WO2022220767A1 - A pharmaceutical product for prophylaxis and treatment of viral diseases caused by coronavirus (sars-cov-2 or covid-19) - Google Patents
A pharmaceutical product for prophylaxis and treatment of viral diseases caused by coronavirus (sars-cov-2 or covid-19) Download PDFInfo
- Publication number
- WO2022220767A1 WO2022220767A1 PCT/TR2021/051615 TR2021051615W WO2022220767A1 WO 2022220767 A1 WO2022220767 A1 WO 2022220767A1 TR 2021051615 W TR2021051615 W TR 2021051615W WO 2022220767 A1 WO2022220767 A1 WO 2022220767A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- pharmaceutical product
- range
- product according
- cineole
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 33
- 229940127557 pharmaceutical product Drugs 0.000 title claims abstract description 33
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 15
- 201000010099 disease Diseases 0.000 title claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims abstract description 13
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 9
- 238000011321 prophylaxis Methods 0.000 title description 6
- 230000003612 virological effect Effects 0.000 title description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims abstract description 44
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims abstract description 24
- 230000005764 inhibitory process Effects 0.000 claims abstract description 19
- 238000009472 formulation Methods 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims abstract description 12
- 239000000341 volatile oil Substances 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 6
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 claims description 30
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 20
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 claims description 16
- BQOFWKZOCNGFEC-UHFFFAOYSA-N carene Chemical compound C1C(C)=CCC2C(C)(C)C12 BQOFWKZOCNGFEC-UHFFFAOYSA-N 0.000 claims description 16
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 claims description 15
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 claims description 15
- 230000000840 anti-viral effect Effects 0.000 claims description 14
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 claims description 12
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 claims description 10
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 claims description 10
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 claims description 10
- 229930006722 beta-pinene Natural products 0.000 claims description 10
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 claims description 10
- 235000001510 limonene Nutrition 0.000 claims description 10
- 229940087305 limonene Drugs 0.000 claims description 10
- 244000166124 Eucalyptus globulus Species 0.000 claims description 9
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- OGLDWXZKYODSOB-UHFFFAOYSA-N α-phellandrene Chemical compound CC(C)C1CC=C(C)C=C1 OGLDWXZKYODSOB-UHFFFAOYSA-N 0.000 claims description 8
- 241000379194 Abies sibirica Species 0.000 claims description 7
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 claims description 6
- 229930006739 camphene Natural products 0.000 claims description 6
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 claims description 6
- 229930006737 car-3-ene Natural products 0.000 claims description 6
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 5
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 5
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 5
- 229940116229 borneol Drugs 0.000 claims description 5
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 5
- OGLDWXZKYODSOB-SNVBAGLBSA-N alpha-phellandrene Natural products CC(C)[C@H]1CC=C(C)C=C1 OGLDWXZKYODSOB-SNVBAGLBSA-N 0.000 claims description 4
- 229940115397 bornyl acetate Drugs 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000010642 eucalyptus oil Substances 0.000 claims description 4
- 229940044949 eucalyptus oil Drugs 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000007922 nasal spray Substances 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 description 12
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000017807 phytochemicals Nutrition 0.000 description 3
- 229930000223 plant secondary metabolite Natural products 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241001529742 Rosmarinus Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000010645 fir oil Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000012873 virucide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
Definitions
- the invention relates to a pharmaceutical product which is effective in inhibiting ACE2 and developed for use in the prophylaxis and treatment of the diseases such as coronavirus.
- the angiotensin converting enzyme 2 (ACE2) is an enzyme bound to the outer surface of the cells (cell membrane) in the arteries, lungs, kidneys, heart, nasal mucosa and intestines.
- the ACE2 enzyme is involved in the natural balance of our body, and there are pathologies which can be associated with this enzyme. Especially since December 2019, this enzyme has come to the fore in the infections caused by the Coronavirus (Covid-19) which has caused the serious health problems and deaths throughout the world, and a wide variety of the pharmaceutical products which are believed to be effective against the coronavirus through the ACE-2 enzyme inhibition have been tried, and the studies and publications have been made.
- the ACE2 enzyme has been recognized as the specific receptor of the SARS-COV-2 virus. The strong interaction of the S protein of the SARS-COV-2 virus and the catalytic domain of the ACE2 enzyme is the first step in the development of the corona disease.
- Alpha-Pinene the major compound of the fir essential oil (Abies sibirica), is an organic compound of the terpene class, one of two isomers of pinene.
- 1 ,8-cineole is a terpenic aromatic main component of many plants including salvia, rosemary, myrrh, myrtle leaf, tea tree oil and eucalyptus leaves.
- Abies sibirica and Eucalyptus (1,8-cineole) essential oil for the antiviral activity such as HN group, HIV, Herpes simplex (HSV-1)
- HN group HN group
- HIV Herpes simplex
- SARS-COV-2 coronavirus
- the effectiveness of the pharmaceutical product found as a result of the study is not included in the state of the art.
- An object of the invention is to use the pharmaceutical product showing the antiviral activity on the coronavirus (SARS-COV-2) in the prophylaxis and treatment of the disease.
- SARS-COV-2 coronavirus
- Another object of the invention is to use the pharmaceutical product representing the inhibition of the ACE2 receptor in the prophylaxis and treatment of the disease.
- Abies sibirica (alpha-pinene), preferably abies sibirica essential oil, Eucalyptus (1,8-cineole), preferably eucalyptus globulus essential oil, and pure 1,8-cineole used in the formulation of the pharmaceutical product of the invention represent the antiviral activity on the coronavirus (SARS-COV-2) and inhibit the intracellular replication of the virus by inhibiting the ACE2 receptors.
- the formulation of the invention comprises the standardized products of plant origin and will be used in the prophylaxis and treatment of the diseases such as coronavirus in such a way that it will be effective in terms of the ACE2 inhibition.
- the natural active ingredients in the invention are standardized according to the pharmacopoeia.
- the standardized raw material comprises the same amount of the active ingredient in the same quality for each production batch, for each bottle in the batch, and for each drop in the bottle.
- the fir oil comprises alpha pinene within the standard ranges in order to obtain a standardized product.
- the natural components used in the invention are Abies sibirica (the standardized major compound there of is alpha pinene), and/or Eucalyptus (the standardized compound there of is 1,8-cineole), and 1 ,8-cineole as pure substance.
- Abies sibirica the standardized major compound there of is alpha pinene
- Eucalyptus the standardized compound there of is 1,8-cineole
- 1 ,8-cineole as pure substance.
- the activities of the compounds are measured based on the major compounds thereof or the phytochemical to which they are standardized. Therefore, the standardized product formulation of the raw materials has been emphasized in the invention, independently of the effect of alpha pinene and cineole.
- the invention is specifically an in-vitro applied study of the inhaler drop product showing the ACE2 enzyme inhibition and showing the antiviral activity on coronavirus (COVID-19 (SARS-COV-2)).
- the formulation in the pharmaceutical product of the invention prevents the occurrence of the corona disease by inhibiting the strong interaction of the S protein of the SARS-COV-2 virus and the catalytic domain of the ACE2 enzyme.
- the formulation of the pharmaceutical product of the invention for the treatment and/or prevention of the coronavirus disease (COVID-19 (SARS-COV-2)) in humans and/or for the inhibition of the ACE2 receptor comprises, in the predetermined proportions, a pure active ingredient 1 ,8-Cineole which is isolated from any essential oil or synthetically obtained.
- the formulation of the pharmaceutical product of the invention comprises, more specifically, the fir needle oil (Abies sibirica), preferably at least one component of the fir needle oil in the predetermined proportions, and/or Eucalyptus (1 ,8-Cineole), preferably at least one component of eucalyptus essential oil, and 1,8-Cineole in pure form in the predetermined proportions.
- the fir needle oil (Abies sibirica)
- Eucalyptus (1 ,8-Cineole) preferably at least one component of eucalyptus essential oil, and 1,8-Cineole in pure form in the predetermined proportions.
- the fir needle oil which is used in the invention as an active ingredient comprises alpha pinene in the range of 10.0 to 25.0% by weight, camphene in the range of 5.0 to 28.0% by weight, beta pinene in the range of 1.0 to 30.0% by weight, car-3-ene in the range of 1.0 to 15.0% by weight, limonene in the range of 4.0 to 30.0% by weight, bornyl acetate in the range of 5.0 to 35.0% by weight, and borneol in the range of 1 to 5% by weight.
- the fir needle oil comprises, in the standardized proportions of the component contained therein, 19.4% by weight of alpha pinene, 16.7% by weight of camphene, 17.7% by weight of beta pinene, 11.1% by weight of car-3-ene, 13.7% by weight of limonene, 7.7% by weight of bornyl acetate, and 2.4% by weight of Borneol.
- the eucalyptus oil which is used in the invention as another active ingredient comprises alpha pinene in the range of 0.05 to 10.0% by weight, beta pinene in the range of 0.05 to 1.5% by weight, alpha-phellandrene in the range of 0.05 to 1.5% by weight, limonene in the range of 0.05 to 15.0% by weight, and more than 60% by weight of 1,8-Cineole.
- Active ingredient in question eucalyptus oil comprises, in the standardized proportions of the component contained therein, 2.7% by weight of alpha pinene, 0.5% by weight of beta pinene, 0.7% by weight of alpha-phellandrene, 8% by weight of limonene, and 80.5% by weight of 1 ,8-Cineole.
- the formulation of the pharmaceutical product of the invention comprises, in the standardized proportions of the component contained therein, 13.16% of alpha pinene and/or 10.98% of camphene and/or 10.77% of beta pinene and/or 7.06% of car-3-ene (delta-3-Carene) and/or 13.66% of limonene and/or 30.98% of 1,8-Cineole and/or 0.95% of Borneole.
- the formulation of the pharmaceutical product of the invention is in the form of the inhaler drop or in a form administered by inhalation or transdermally, or in the form of gum or capsule or cream or pomade or tablet or rapimelt or inhalation liquid or bath water or syrup or transdermal patch or nasal spray or throat spray or lozenge or soft capsule or nasal cream, but it is not limited thereto.
- the formulation which is preferably in the form of drop in the pharmaceutical product is dripped onto the collar, it has a mechanical effect on the patient when the vapor phase is delivered into the nose by inhalation and penetrates into the respiratory organs.
- the pharmaceutical product of the invention provides an inhibition of more than 70% in the effective amount, i.e., in the concentration of 20 micrograms/mL, with its enzymatic activity in terms of the ACE2 enzyme inhibition.
- the in-vitro experiments are carried out.
- the pharmaceutical product of the invention is an antiviral (virucidal, virucide) and is an ACE2 inhibitory agent.
- the in-vitro experiments comprising the following steps are carried out.
- the antiviral activity and ACE2 action mechanism of the formulation of the invention works as follows: By dripping the formulation for inhalation in a close proximity so as to be inhaled in the nasal cavity, the product which passes into the vapor phase has a barrier effect on the mucosa in the nasal cavity and kills the viruses on the mucosa.
- the virus stock culture is prepared using the Vero E6 cell line proliferated with DMEM- 10 (Dulbecco’s Minimum Essential Medium with pen/strep/fungizone containing 10% FBS (fetal bovine serum)).
- DMEM- 10 Dulbecco’s Minimum Essential Medium with pen/strep/fungizone containing 10% FBS (fetal bovine serum)
- FBS fetal bovine serum
- the pharmaceutical product of the invention the effectiveness of which is tested against the COVID-19 (SARS-COV-2) virus (Clinical isolate, GenBank No: MT955161.1), is proven to kill the viruses by 79.89% in the 5 th minute and by 93.23% in the 30 th minute.
- the virus suspension is dripped onto the area of 2 cm 2 on the stainless-steel disc specified in the standards TS EN 16777: 2019 and left to dry in the biosafety cabinet. After the discs are dried, 4 control discs are left in the biosafety cabinet in the laboratory and 6 test discs are placed in a 15 L plastic container with a lid. After 5-6 drops of inhaler drop are dropped on the fabric in the plastic container, the lid of the container is closed.
- the exposure time of the viruses to the vapor of the drop of the invention is between 5 and 30 minutes and the ambient temperature is 30 ⁇ 1°C.
- the medium for the virus cell incubation is 37 ⁇ 1°C, 5% CO2.
- test results for the antiviral activity of the pharmaceutical product of the invention are shown in Table 1.
- * 0-4 refer to % of cpe ⁇ 0: no cpe; 1 25%: 2: 50%: 3: 75%; 4: 100%)
- the substances are dissolved in DMSO (Dimethyl sulfoxide) in order to test whether the formulation inhibits the ACE2 enzyme.
- DMSO Dimethyl sulfoxide
- the effect of DMSO is eliminated and the amount of DMSO in the solutions is reduced to less than 1% in order to analyze the actual enzyme inhibition of the test substances.
- the enzyme inhibitions of the substances are calculated by the comparison in accordance with the standards included in the kit. In the presence of an ACE2-specific inhibitor, the enzyme loses its peptidase activity, resulting in a decrease in the fluorescence intensity. Based on this decrease, an inhibition value of 70% for the product of the invention and an inhibition value of more than 85% for the pure 1 ,8-Cineole used in the product of the invention are calculated.
- Graph-1 Activity table of the pharmaceutical product with the formulation of the invention and of 1,8-Cineole as a pure substance in ACE2 enzyme inhibition
- the pharmaceutical product of the invention is an effective and natural product against the coronavirus which is critical for the human health.
- the pharmaceutical product of the invention is directed to the prevention and treatment of the coronavirus disease and can be applied to industry and the health sector as a self- administered prevention and treatment agent.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2021/006518 TR2021006518A2 (tr) | 2021-04-13 | KORONAVİRÜS (SARS-COV-2 veya COVID-19) KAYNAKLI VİRAL HASTALIKLARIN PROFİLAKSİSİ VE TEDAVİSİ İÇİN BİR FARMASÖTİK ÜRÜN | |
| TR2021/006518A TR202106518A2 (tr) | 2021-04-13 | 2021-04-13 | KORONAVİRÜS (SARS-COV-2 veya COVID-19) KAYNAKLI VİRAL HASTALIKLARIN PROFİLAKSİSİ VE TEDAVİSİ İÇİN BİR FARMASÖTİK ÜRÜN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022220767A1 true WO2022220767A1 (en) | 2022-10-20 |
Family
ID=77615034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2021/051615 WO2022220767A1 (en) | 2021-04-13 | 2021-12-30 | A pharmaceutical product for prophylaxis and treatment of viral diseases caused by coronavirus (sars-cov-2 or covid-19) |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR202106518A2 (tr) |
| WO (1) | WO2022220767A1 (tr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023091111A1 (en) * | 2021-11-18 | 2023-05-25 | İstanbul Medi̇pol Üni̇versi̇tesi̇ | Ace-2 enzyme inhibitory effects of essential oils obtained from the aerial parts of eucalyptus globulus and eucalyptus citriodora plants |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009245A1 (en) * | 2000-04-03 | 2004-01-15 | Vail William Banning | Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS) |
-
2021
- 2021-04-13 TR TR2021/006518A patent/TR202106518A2/tr unknown
- 2021-12-30 WO PCT/TR2021/051615 patent/WO2022220767A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009245A1 (en) * | 2000-04-03 | 2004-01-15 | Vail William Banning | Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS) |
Non-Patent Citations (2)
| Title |
|---|
| ASIF M ET AL.: "COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties", INFLAMMOPHARMACOLOGY, vol. 28, no. 5, 14 August 2020 (2020-08-14), pages 1153 - 1161, XP037257443, DOI: 10.1007/s 10787-020-00744-0 * |
| DA SILVA, J.K.R. ET AL.: "Essential oils as antiviral agents, potential of essential oils to treat SARS-CoV-2 infection: an in-silico investigation", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 10, 12 May 2020 (2020-05-12), pages 3426, XP055787017, DOI: 10.3390/ijms21103426 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TR202106518A2 (tr) | 2021-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thabrew et al. | Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay | |
| JP2000119188A (ja) | ヒト免疫不全ウイルスおよびその他感染性疾患の抗菌予防と治療 | |
| Santhi et al. | Therapeutic potential of phytoconstituents of edible fruits in combating emerging viral infections | |
| WO2019089165A1 (en) | Orally administered composition for treating cystic fibrosis, copd, asthma and other inflammatory conditions | |
| TWI679985B (zh) | 含有橄欖果實萃取物的Ｔｉｅ２活化劑 | |
| WO2022220767A1 (en) | A pharmaceutical product for prophylaxis and treatment of viral diseases caused by coronavirus (sars-cov-2 or covid-19) | |
| Kontogiannis et al. | Antiviral activity of bee products | |
| Rollando et al. | In vitro Cytotoxic Potential of Sterculia quadrifida Leaf Extract Against Human Breast Cancer Cell Lines. | |
| WO2017013568A1 (en) | Anti-herpes composition and anti-herpes pharmaceutical formulation | |
| Khodadadi | Administration of Galega officinalis in experimental and clinical investigations; a narrative review | |
| Al Naggar et al. | Back to ancient remedy: could inhalation of aerosolised-honey and propolis tincture protect against the COVID-19 pandemic | |
| Harun et al. | The effects of individual and combination of asiatic acid and madecassoside derived from Centella asiatica (Linn.) on the viability percentage and morphological changes of mouse macrophage cell lines (J774A. 1) | |
| KR20240016954A (ko) | 분별된 꿀을 사용한 병태 치료용 조성물 및 방법 | |
| TR2021006518A2 (tr) | KORONAVİRÜS (SARS-COV-2 veya COVID-19) KAYNAKLI VİRAL HASTALIKLARIN PROFİLAKSİSİ VE TEDAVİSİ İÇİN BİR FARMASÖTİK ÜRÜN | |
| CA2622508C (en) | Medicament for the prevention and treatment of influenza | |
| CN111345288A (zh) | 一种可以在呼吸防护器表面形成杀菌抗病毒涂层的胶性载体、胶性酊剂和应用 | |
| de Armas et al. | In vitro antiviral activity of Rhizophora mangle L. aqueous bark extract and the butanolic fraction against Canine Distemper Virus and Bovine Herpes Virus type 1 | |
| WO2022218238A1 (zh) | 中草药组合物及其食品、清洁剂、保养品及其用于制备冠状病毒治疗药及肠病毒治疗药的用途 | |
| US20080274214A1 (en) | Medicament For The Prevention and Treatment Of Influenza | |
| Shi | Back to Ancient Remedy: Could Inhalation of Aerosolised-Honey and Propolis Tincture Protect Against the COVID-19 Pandemic? | |
| Singla et al. | Discovering the Combined In-vitro Anti-inflammatory Effects of Smilax glabra Standardized Rhizome Extract and Berberis aristata Standardized Root Extract | |
| Masalu et al. | Antibacterial and Anti-HIV-1 GP120 Activities of Selected Medicinal Plants. | |
| Soltane et al. | Antiviral properties of clove (Syzygium aromaticum) | |
| Nkono et al. | Free Radical Scavenging Activity of Cymbopogon Citratus (Stapf) and Evaluation of its Antiproliferative Effect on MG-63 Human Osteosarcoma Cells | |
| Mondal et al. | Utilization of Natural Compounds for Treatment of Tuberculosis-I |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21937121 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |